• 대한생식의학회:학술대회논문집
• /
• 2003.06a
• /
• pp.47-53
• /
• 2003

• Development and Reproduction
• /
• v.4 no.1
• /
• pp.61-66
• /
• 2000

This study was investigated to analyze the inactivating point mutation and expression level of follicle-stimulating hormone(FSH) receptor mRNA. In first experiment, we analyzed the point mutation. Peripheral blood was collected from each patient. To screen individuals for the C566T mutation, PCR was performed for exon 7 of the FSH receptor gene in 10 patients. No inactivating point mutation of FSH receptor gene was identified in women with premature ovarian failure. To analyze the expression level of FSH receptor, mRNA expressions were examined by RT-PCR method using specific primers for the FSH receptor. The amount of FSH receptor mRNA expressed in POF patients was lower than that in the control group. But it was not significantly different. These finding suggests that lower expression of FSH receptor in premature ovarian failure patients might be the cause of the low response to the gonadotropin during the hyperstimulation in IVF-ET cycles.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.35 no.1
• /
• pp.12-33
• /
• 2022

Objectives: Since the importance of Korean Medicine (KM) treatment for Poor Ovarian Response (POR) is high, we intend to present appropriate treatment standards and methods by analyzing information on KM knowledge presented in related research papers and literature. Methods: First, research papers dealing with Diminished Ovarian Reserve (DOR) and POR are analyzed. In addition, we analyze and refer to research papers on Premature Ovarian Failure and Premature Menopause, which are closely related to DOR. Results: It is considered that the application of KM treatment alone for DOR should be based on the age that best reflects the ovarian reserve rather than the value of the ovarian reserve-related index centered on Anti-Müllerian Hormine (AMH). Accordingly, as a DOR woman under the age of 38, if normal sexual intercourse is achieved and the spouse factor is excluded, KM treatment, focusing on herbal medicine and acupuncture, can be applied. Conclusions: Korean Medicine treatment for infertility caused by decreased ovarian reserve is expected to be effective. However, research on specific treatments and targets will have to be added.

• Clinical and Experimental Reproductive Medicine
• /
• v.41 no.3
• /
• pp.120-124
• /
• 2014

Objective: The aim of the present study was to examine whether interactions between polymorphisms in the thyroglobulin and ADAM metallopeptidase with thrombospondin type 1 motif, 16 (ADAMTS16) genes are associated with the development of premature ovarian failure (POF). Methods: A total of 75 patients with POF and 196 controls were involved in this study. We used a GoldenGate assay to genotype single nucleotide polymorphisms (SNPs). Logistic regression analysis was performed to identify POF-associated polymorphisms and synergistic interactions between polymorphisms in the thyroglobulin and ADAMTS16 genes. Results: Single gene analyses using logistic regression analysis showed no significant association between polymorphisms in the two genes and POF. In the results from interaction analyses, we found seven synergistic interactions between the polymorphisms in thyroglobulin and ADAMTS16, although there was no combination showing p-values lower than the significant threshold using the Bonferroni correction. When the AG genotype was present at the rs853326 missense SNP, the A and G alleles at the tagging SNPs rs16875268 and rs13168665 showed significant interactions (odds ratios=5.318 and 16.2 respectively; 95% confidence intervals, 1.64-17.28 and 2.08-126.4; p=0.0054 and 0.0079). Conclusion: Synergistic interactions between polymorphisms in the thyroglobulin and ADAMTS16 genes were associated with an increased risk of POF development in Korean women.

• The Journal of Korean Obstetrics and Gynecology
• /
• v.32 no.4
• /
• pp.170-180
• /
• 2019

Objectives: The purpose of this study is to report the case of Korean medicine treatment on primary ovarian insufficiency. Methods: The patient in this case was 29-year-old female who was diagnosed with primary ovarian insufficiency. She had irregular menstruation and hypomenorrhea more than 6 months. She also suffered from hot flash and vaginal dryness. She was treated over 1 year with Korean medicine treatment, such as herbal medicine, acupuncture, and pharmacopuncture. We assessed the clinical symptoms, menstrual status and serum hormone level during the treatment. Results: After treatment, symptoms of primary ovarian insufficiency were relieved, level of serum FSH decreased and level of serum E2 increased. We maintained the treatment over 1 year and kept follow-up measurements of serum hormone level. Conclusions: This study shows that Korean medicine treatment can be effective in treating primary ovarian insufficiency. The report suggests the long treatment procedure for primary ovarian insufficiency.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.12
• /
• pp.4759-4763
• /
• 2014

Radiation therapy in ovarian cancers has been considered an outdated concept for many years, mainly due to its toxicity and failure to show benefit in terms of survival. Chemotherapy has been extensively used after surgery for these cancers and it has almost replaced radiation therapy as an adjuvant treatment. Nevertheless, failures in ovarian cancers continue to occur even with the use of newer and effective chemotherapy regimens. About 70% patients demonstrate recurrence in the abdomen or pelvis after first line chemotherapy in ovarian cancers. With advances in technology and sophistication of radiation techniques, along with the molecular and biological knowledge of distinct histological subtypes, there is a need to redefine the role of radiation therapy. This review article focuses on the literature on use of radiation in ovarian cancers and its rationale and indications in the present day. For this, a literature pub med/medline search was performed from January 1975 to March 2014 to redefine the role of radiotherapy in ovarian cancers.

• The Korea Genome Conference
• /
• 2006.09a
• /
• pp.48-48
• /
• 2006

• Clinical and Experimental Reproductive Medicine
• /
• v.35 no.4
• /
• pp.239-245
• /
• 2008

• 대한생식의학회:학술대회논문집
• /
• 2006.06a
• /
• pp.18-20
• /
• 2006

• The Korea Genome Conference
• /
• 2005.09a
• /
• pp.48-48
• /
• 2005